Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GRT-R904
- Development stage
- Unknown
- Lead developer
- Gritstone Oncology
- Modality
- Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular (adenoviral Prime), Intramuscular (mRNA Boost)
01
Overview
GRT-R904 is a neoantigen-based therapeutic cancer vaccine designed to stimulate the immune system to recognize and destroy tumor cells. It consists of tumor-specific shared neoantigens, which are immunogenic and unique across subsets of patients. The vaccine is administered in combination with immune checkpoint inhibitors (nivolumab and ipilimumab) for the treatment of advanced or metastatic solid tumors, including non-small cell lung cancer (NSCLC), microsatellite-stable colorectal cancer (MSS-CRC), pancreatic ductal adenocarcinoma, and other shared neoantigen-positive tumors. The mechanism involves priming the immune system against specific mutations such as KRAS and TP53 using an adenovirus-based prime followed by a self-amplifying mRNA boost[1][2][3][5][6].
- Other names
- neoantigen-based therapeutic cancer vaccine GRT-R904
02
Targets
TP53-neoantigen-MHC-I (TP53 mutant neoantigen peptides presented by Major Histocompatibility Complex class I)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on GRT-R904.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GRT-R904.